Le Lézard
Classified in: Science and technology
Subjects: Conference, Product/Service, Trade Show

AffiniPay Launches AffiniPay IQ, Generative AI for Legal Tech Industry


AffiniPay, the leader in online payments and software solutions for professionals, announced today the launch of generative AI embedded in its leading legal technology products, MyCase, CASEpeer, LawPay, and Docketwise.

"At AffiniPay, we believe generative AI can drive the type of efficiencies and insights that will result in better outcomes for our customers and their clients," said Dru Armstrong, Chief Executive Officer of AffiniPay, parent company of MyCase, CASEpeer, LawPay, and Docketwise. "As a trusted technology partner, we have big plans to empower our customers with AI, and are excited to announce the launch of AffiniPay IQ."

According to the newly released 2024 LawPay and MyCase Legal Industry Report, productivity is a key driver for generative AI investment, with 75% of law firms citing it as the top reason for their interest in AI. To meet this demand, AffiniPay is investing in generative AI and plans to roll out new solutions in a phased manner across the legal product suite. Starting with a MyCase beta, AffiniPay plans to extend various AI solutions to CASEpeer, LawPay, and Docketwise in the coming months.

The company's vision is that customers will be able to utilize AI-powered conversational interface that will enable users to access their data and generate insights using natural language, directly within the interface. These future features will include:

The first beta release of AffiniPay IQ features include document summarization and text editing, both of which will be woven seamlessly into the suite of AffiniPay's legal products. Starting with MyCase and CASEpeer, the following AI features will be built into daily workflows:

"We are committed to our responsible approach to innovation, and are excited to launch generative AI functionality into our software that serves our customers and their needs, and no one else," said Bryan Thompson, Chief Technology Officer of AffiniPay. "This is the first of many thoughtful generative AI features that our team will be weaving into our product suite over the coming months."

The second release of AffiniPay IQ features will include:

AffiniPay invites legal professionals to experience AffiniPay IQ from Jan. 29 - Feb. 2, during Legalweek in New York, where both LawPay and MyCase are sponsors.

For more information about AffiniPay IQ, please visit affinipay.com/ai-software/. To sign up for the MyCase beta waitlist, please visit mycase.com/products/legal-ai-software/.

About AffiniPay

AffiniPay is a market leader in practice management software and online payments for professionals serving legal, accounting, architectural, engineering, and construction firms. AffiniPay has been recognized as one of Inc. 5000's fastest-growing companies for 12 years in a row. Each of its brands leads the market it serves with solutions purpose-built by industry including LawPay, MyCase, CASEpeer, Docketwise, CPACharge, and AffiniPay for Associations. AffiniPay's solutions are trusted by more than 245,000 legal & accounting professionals with more than 150 strategic partnerships and endorsements, including the American Bar Association and the American Institute of Certified Public Accountants. Visit affinipay.com to learn more.


These press releases may also interest you

at 07:10
POSaBIT Systems Corporation (the "Company" or "POSaBIT") announces today that the Company is anticipating a delay in filing its annual financial statements and accompanying management's discussion and analysis for the year ended December 31, 2023...

at 07:06
Recently, at Auto China 2024, Neusoft Corporation (Neusoft, SSE:600718) launched OneCoreGo® Global In-Vehicle Intelligent Mobility Solutions 5.0, showcasing its innovative achievements in the AI+ Automotive field. It's also one of the series of...

at 07:05
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor...

at 07:05
Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective...

at 07:05
Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it has entered into a definitive merger...

at 07:05
bit.bio, the company coding human cells for novel cures, and a pioneer in the field of synthetic biology, today announces it will participate in an engaging fireside chat at SynBioBeta 2024 featuring Nobel Laureate Thomas Südhof and bit.bio founder...



News published on and distributed by: